Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

4
results for

"Tae Hee Lee"

Article category

Keywords

Publication year

"Tae Hee Lee"

Guideline

Steatotic liver disease

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee, Yong Kyun Cho, on behalf of The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol 2021;27(3):363-401.
Published online June 22, 2021
DOI: https://doi.org/10.3350/cmh.2021.0178

Citations

Citations to this article as recorded by  Crossref logo
  • Quinoa bran terpenoids ameliorates metabolic dysfunction-associated steatotic liver disease by enriching of L. murinus LQ719
    Qinqin Qiao, Shuhua Shan, Huiqin Guo, Ning An, Jiangying Shi, Zhuoyu Li
    Food Research International.2026; 225: 118084.     CrossRef
  • Effects of Intermittent Calorie Restriction in Nondiabetic Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
    Han Ah Lee, Hyeyoung Moon, Yuri Kim, Jeong Kyong Lee, Hye Ah Lee, Hwi Young Kim
    Clinical Gastroenterology and Hepatology.2025; 23(1): 114.     CrossRef
  • Serum Ferritin Levels and Liver‐Related Events in Individuals With Steatotic Liver Disease: A Longitudinal Cohort Study
    Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
    Alimentary Pharmacology & Therapeutics.2025; 61(3): 491.     CrossRef
  • Differential Exercise Requirements for Nonalcoholic Fatty Liver Disease Resolution Across Age Groups: A Longitudinal Study of Korean Military Officers
    Jaejun Lee, Dong Yeup Lee, Jae Hyeop Jung, Eunkyoung Bae, Jeong A. Yu, Hyun Yang
    Journal of Physical Activity and Health.2025; 22(3): 323.     CrossRef
  • The Role of microRNA-22 in Metabolism
    Simone Tomasini, Paolo Vigo, Francesco Margiotta, Ulrik Søberg Scheele, Riccardo Panella, Sakari Kauppinen
    International Journal of Molecular Sciences.2025; 26(2): 782.     CrossRef
  • Performance of Noninvasive Indices for Discrimination of Metabolic Dysfunction-Associated Steatotic Liver Disease in Young Adults
    Jaejun Lee, Chang In Han, Dong Yeup Lee, Pil Soo Sung, Si Hyun Bae, Hyun Yang
    Gut and Liver.2025; 19(1): 116.     CrossRef
  • Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease
    Mei-jing Chen, Ying Chen, Jin-qing Lin, Rong Hu, Dun Liu, Jing-yi Chen, Ka Li, Xiao-ying Jiang
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Diagnostic Accuracy of Non-Invasive Diagnostic Tests for Nonalcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis
    Yuxin Sun, Die Hu, Mingkun Yu, Shi-Bing Liang, Youyou Zheng, Xin Wang, Guangdong Tong
    Clinical Epidemiology.2025; Volume 17: 53.     CrossRef
  • Cardiovascular Risk From Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factor Count, and Their Longitudinal Changes: A Nationwide Cohort Study
    Hyeok-Hee Lee, Han Ah Lee, Eun-Jin Kim, Hwi Young Kim, Hyeon Chang Kim, Sang Hoon Ahn, Hokyou Lee, Seung Up Kim
    American Journal of Gastroenterology.2025; 120(10): 2321.     CrossRef
  • Comparing non-alcoholic fatty liver disease indices in predicting the prevalence and incidence of metabolic syndrome in middle-aged adults
    Byung Sik Kim, Hyun-Jin Kim, Seong Won Jeon, Kyung Hwan Kim, Dong Wook Kim, Jeong-Hun Shin
    Heliyon.2025; 11(7): e43073.     CrossRef
  • Impact of cardiometabolic risk factors on hepatic fibrosis and clinical outcomes in MASLD: A population-based multi-cohort study
    Huiyul Park, Terry Cheuk-Fung Yip, Eileen L. Yoon, Grace Lai-Hung Wong, Hye Sun Lee, Vincent Wai-Sun Wong, Jimmy Che-To Lai, Dae Won Jun
    JHEP Reports.2025; 7(6): 101388.     CrossRef
  • KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025
    Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang
    Clinical and Molecular Hepatology.2025; 31(Suppl): S1.     CrossRef
  • The association between modified cardiometabolic index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study
    Yanjun Guo, Wei Su, Lulong Tao, Guoxin Zhang, Kun Wang
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Sex differences in the mediation of the MASLD - Depression association by fat distribution in U.S. adults
    Changhuai He, Liuxin Zhou, Tianming Gao, Runmin Cao, Chuanqi Cai, Guoqing Jiang
    Acta Psychologica.2025; 256: 105041.     CrossRef
  • Association Between Perfluoroalkyl Substance (PFAS) Exposure and Nonalcoholic Fatty Liver Disease in Korean Adults: Results From the KoNEHS 2018–2020: A Cross‐Sectional Study
    Jisuk Yun, Young‐Sun Min
    American Journal of Industrial Medicine.2025; 68(7): 588.     CrossRef
  • Valorization of grape pomace by microbial fermentation: Composition, biological activities and potential applications for the food industry
    Kavindya Samarakoon, H.P. Vasantha Rupasinghe
    Journal of Food Composition and Analysis.2025; 144: 107656.     CrossRef
  • Managing Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care Settings: A Review
    Vignesh Rajan, Ambarish Das, J. Venkatachalam, K. K. Lohani, Chandrakant Lahariya
    Preventive Medicine: Research & Reviews.2025; 2(4): 183.     CrossRef
  • Cost-effectiveness analysis of MASLD screening using FIB-4 based two-step algorithm in the medical check-up
    Mimi Kim, Huiyul Park, Eileen L. Yoon, Ramsey Cheung, Donghee Kim, Hye-Lin Kim, Dae Won Jun
    Scientific Reports.2025;[Epub]     CrossRef
  • Are mesenchymal stem/stromal cells a novel avenue for the treatment of non-alcoholic fatty liver disease?
    Milton Artur Ruiz, Roberto Luiz R Kaiser Junior, Gabriel Piron-Ruiz, Luiz Gustavo de Quadros
    World Journal of Stem Cells.2025;[Epub]     CrossRef
  • The ameliorative effect of C-Kit+ hepatic endothelial cells with Mertk deficiency on nonalcoholic steatohepatitis
    Seng-Wang Fu, Yu-Xuan Gao, Hui-Yi Li, Jun-Cheng Wu, Zheng-Hong Li, Ming-Yi Xu
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2025; 1871(7): 167964.     CrossRef
  • Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease
    Eiji Kakazu, Masaaki Mino, Tatsuya Kanto
    Clinical and Molecular Hepatology.2025; 31(3): 771.     CrossRef
  • Chemical profile of Ficus lyrata bark extract and its therapeutic effect on non-alcoholic fatty liver disease via regulating oxidative stress, inflammation and hepatic lipogenesis
    Amria Mamdouh Mousa, Rehab Fikry Taher, Nermin Mohamed El-Sammad, Esraa Aly Balabel, Elham Mohamed Youssef, Ahmed Hassan Afifi, Sahar Samir Abdel-Rahman, Nayera Anwar, Sherien Kamal Hassan
    BMC Complementary Medicine and Therapies.2025;[Epub]     CrossRef
  • Metabolic Dysfunction–Associated Steatotic Liver Disease, Alcohol Consumption, and the Risk of Atrial Fibrillation: A Nationwide Population‐Based Study
    Minkwan Kim, Minkook Son, Sang Yi Moon, Yang Hyun Baek
    Journal of the American Heart Association.2025;[Epub]     CrossRef
  • Comparison of sarcopenia screening indices using serum creatinine and cystatin C in metabolic dysfunction-associated steatotic liver disease
    Inyoung Hwang, Shi-Ra Lee, Yun Kim, Sang Won Lee
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Exercise training improves metabolic and circulatory function in COPD patients with NAFLD: evidence from clinical and molecular profiling
    Yi-cai Qian, Xiaoxiang Liu, Panpan Liu, ShuYing Jia, Yi Ding, Cuiling Zhu, Jing He
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease
    Yunmi Ko, Moon Haeng Hur, Youngsu Park, Jeayeon Park, Hyunjae Shin, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
    Gut and Liver.2025; 19(5): 758.     CrossRef
  • Diet and Lifestyle Interventions in Metabolic Dysfunction-Associated Fatty Liver Disease: A Comprehensive Review
    Muhammad Y. Sheikh, Muhammad F. Younus, Annie Shergill, Muhammad N. Hasan
    International Journal of Molecular Sciences.2025; 26(19): 9625.     CrossRef
  • Association of Rapid Early Weight Loss with One-Year Hepatic Steatosis Improvement After Sleeve Gastrectomy: A Retrospective Cohort Study
    Min Kyoung Jang, Si Yeol Yoon, Jin A. An, Ji Soo Kim, Min-Seon Kim, Jung Ah Lee, Chang Seok Ko, Se Hee Min
    Journal of Clinical Medicine.2025; 14(20): 7284.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease in Egypt: Epidemiology, risk factors and management challenges
    Walaa Abdelhamed, Mona Amin, Imam Waked, Mohamed El-Kassas
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Fibrotic Burden in Patients With Hepatitis B Virus–Related Cirrhosis Is Independently Associated With Poorer Kidney Outcomes
    Chan-Young Jung, Hui-Yun Jung, Hyung Woo Kim, Geun Woo Ryu, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim
    The Journal of Infectious Diseases.2024; 229(1): 108.     CrossRef
  • A Comparison of the Prognostic Value of Liver Fibrosis Scores in Acute Myocardial Infarction Patients With and Without Type 2 Diabetes
    Hao-ming He, Shu-wen Zheng, Yi-nong Chen, Long-yang Zhu, Zhe Wang, Si-qi Jiao, Fu-rong Yang, Yi-hong Sun
    Angiology.2024; 75(3): 219.     CrossRef
  • Navigating nonalcoholic fatty liver disease (NAFLD): Exploring the roles of estrogens, pharmacological and medical interventions, and life style
    Qianying Zuo, Nicole Hwajin Park, Jenna Kathryn Lee, Ashlie Santaliz-Casiano, Zeynep Madak-Erdogan
    Steroids.2024; 203: 109330.     CrossRef
  • Association between plant-based diets and risk of metabolic dysfunction–associated steatotic liver disease in Korean adults: A prospective cohort study
    Bayarmaa Nasan Ulzii, Kyungjoon Lim, Sangah Shin
    Nutrition.2024; 128: 112579.     CrossRef
  • Extrahepatic malignancies in metabolic dysfunction‐associated fatty liver disease: A nationwide cohort study
    Min Kyung Park, Moon Haeng Hur, Hye‐Sung Moon, Hyunjae Shin, Sung Won Chung, Sungho Won, Yun Bin Lee, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Jung‐Hwan Yoon, Yoon Jun Kim
    Liver International.2024; 44(3): 799.     CrossRef
  • Performance Evaluation of a Novel Non-Invasive Test for the Detection of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
    Anna Stefanska, Katarzyna Bergmann, Szymon Suwała, Aneta Mankowska-Cyl, Marek Kozinski, Roman Junik, Magdalena Krintus, Mauro Panteghini
    Metabolites.2024; 14(1): 52.     CrossRef
  • Very low-carbohydrate diet with higher protein ratio improves lipid metabolism and inflammation in rats with diet-induced nonalcoholic fatty liver disease
    I-Ting Wu, Wan-Ju Yeh, Wen-Chih Huang, Hsin-Yi Yang
    The Journal of Nutritional Biochemistry.2024; 126: 109583.     CrossRef
  • Quality Evaluation of Metabolic-Associated Fatty Liver Disease Guidelines and Expert Consensus
    Meijing Chen, Ying Chen, Dun Liu, Ka Li, Rong Hu, Jingyi Chen, Xiaoying Jiang, Jinqing Lin
    Hormone and Metabolic Research.2024; 56(07): 509.     CrossRef
  • Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
    Xin Ding, Xu He, Bulang Tang, Tian Lan
    Chinese Medicine.2024;[Epub]     CrossRef
  • Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease
    Heejoon Jang, Yeonjin Kim, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Soo Lim, Woojoo Lee, Won Kim
    JAMA Internal Medicine.2024; 184(4): 375.     CrossRef
  • Mobile App–Based Lifestyle Coaching Intervention for Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial
    Oh Young Kwon, Mi Kyung Lee, Hye Won Lee, Hyerang Kim, Jae Seung Lee, Yeonsoo Jang
    Journal of Medical Internet Research.2024; 26: e49839.     CrossRef
  • Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective
    Jia-Lan Wang, Su-Wen Jiang, Ai-Rong Hu, Ai-Wu Zhou, Ting Hu, Hong-Shan Li, Ying Fan, Ken Lin
    Heliyon.2024; 10(5): e27325.     CrossRef
  • Assessment of Hepatic Steatosis Using Ultrasound-Based Techniques: Focus on Fat Quantification
    Woo Sun Rou
    Clinical Ultrasound.2024; 9(1): 1.     CrossRef
  • Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease
    Hye Kyung Hyun, Hye Won Lee, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
    Gut and Liver.2024; 18(2): 294.     CrossRef
  • The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease
    Hye Won Lee, Kun Hee Kim, Sang Hoon Ahn, Han Chu Lee, Jonggi Choi
    Liver International.2024; 44(6): 1448.     CrossRef
  • Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease
    Yaxin Li, Yitian Guo, Shiyun Tan
    Clinics and Research in Hepatology and Gastroenterology.2024; 48(4): 102320.     CrossRef
  • Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
    Byeong Geun Song, Aryoung Kim, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
    Liver Cancer.2024; 13(5): 561.     CrossRef
  • Sleep factors were associated with a higher risk of MAFLD and significant fibrosis
    Yaxin Li, Shiyun Tan
    Sleep and Breathing.2024; 28(3): 1381.     CrossRef
  • Puerarin Induces Macrophage M2 Polarization to Exert Antinonalcoholic Steatohepatitis Pharmacological Activity via the Activation of Autophagy
    Xiaoxue Fang, Xintian Lan, Ming Zhu, Min He, Mengmeng Sun, Yiming Cao, Difu Zhu, Dean Guo, Haoming Luo
    Journal of Agricultural and Food Chemistry.2024; 72(13): 7187.     CrossRef
  • Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score
    Aryoung Kim, Danbee Kang, Sung Chul Choi, Juhee Cho, Dong Hyun Sinn, Geum-Youn Gwak, Ashraf Elbahrawy
    PLOS ONE.2024; 19(3): e0301126.     CrossRef
  • Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma
    Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim
    Yonsei Medical Journal.2024; 65(7): 371.     CrossRef
  • Diagnostic performances of Fibrosis‐4 index and nonalcoholic fatty liver disease fibrosis score in metabolic dysfunction‐associated steatotic liver disease in Asian primary care clinics
    Huiyul Park, Mimi Kim, Hye‐Lin Kim, Seon Cho, Eileen L. Yoon, Dae Won Jun
    Hepatology Research.2024; 54(11): 1027.     CrossRef
  • Harnessing Metabolic Indices as a Predictive Tool for Cardiovascular Disease in a Korean Population without Known Major Cardiovascular Event
    Hyun-Jin Kim, Byung Sik Kim, Yonggu Lee, Sang Bong Ahn, Dong Wook Kim, Jeong-Hun Shin
    Diabetes & Metabolism Journal.2024; 48(3): 449.     CrossRef
  • An Exploration of the Treatment of Non-Alcoholic Fatty Liver Disease Based on Dietary Factors
    Wanzhou Yang, Y.-T. Yu, P.P. Piccaluga, S. Xie
    BIO Web of Conferences.2024; 111: 03024.     CrossRef
  • Assessing the Utility of Acoustic Radiation Force Impulse in the Evaluation of Non-Alcoholic Fatty Liver Disease with Severe Obesity or Steatosis
    Yeo Wool Kang, Yang Hyun Baek, Jong Hoon Lee, Young Hoon Roh, Hee Jin Kwon, Sang Yi Moon, Min Kook Son, Jin Sook Jeong
    Diagnostics.2024; 14(11): 1083.     CrossRef
  • Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort
    Joo Hyun Oh, Sang Bong Ahn, Seon Cho, Eun-Hee Nah, Eileen L. Yoon, Dae Won Jun
    Journal of Hepatology.2024; 81(5): 772.     CrossRef
  • A Novel Antioxidant, Hydrogen-Rich Coral Calcium Alters Gut Microbiome and Bile Acid Synthesis to Improve Methionine-and-Choline-Deficient Diet-Induced Non-Alcoholic Fatty Liver Disease
    Hung-Tsung Wu, Chin-Shiang Tsai, Ting-Hsing Chao, Horng-Yih Ou, Liang-Miin Tsai
    Antioxidants.2024; 13(6): 746.     CrossRef
  • Emerging mRNA Technology for Liver Disease Therapy
    Ji Wang, Yile Fang, Zhiqiang Luo, Jinglin Wang, Yuanjin Zhao
    ACS Nano.2024; 18(27): 17378.     CrossRef
  • Evaluation of pancreatic iodine uptake and related influential factors in multiphase dual-energy CT
    Chen Pan, Tao Yu, Heng Zhao, Jiani He, Xiaomei Lu, Haiyan Tang, Yang Hong, Chao Shang, Qijun Wu, Aoran Yang, Chunli Li, Minghui Zhou, Yu Shi
    European Radiology.2024; 34(12): 7609.     CrossRef
  • Comparative effects of lifelong moderate-intensity continuous training and high-intensity interval training on blood lipid levels and mental well-being in naturally ageing mice
    Ling Yang, Wentao Lin, Xu Yan, Zhishang Zhang
    Experimental Gerontology.2024; 194: 112519.     CrossRef
  • The Effect of Mobile Lifestyle Intervention Combined with High-Protein Meal Replacement on Liver Function in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Pilot Randomized Controlled Trial
    Eunbyul Cho, Sunwoo Kim, Soonkyu Kim, Ju Young Kim, Hwa Jung Kim, Yumi Go, Yu Jung Lee, Haesol Lee, Siye Gil, Sung Kwon Yoon, Keonho Chu
    Nutrients.2024; 16(14): 2254.     CrossRef
  • Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients
    Maria Eva Argenziano, Mi Na Kim, Michele Montori, Alessandro Di Bucchianico, Daniele Balducci, Sang Hoon Ahn, Gianluca Svegliati Baroni
    Hepatology International.2024; 18(S2): 922.     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    The Korean Journal of Gastroenterology.2024; 84(1): 1.     CrossRef
  • Barriers to care linkage and educational impact on unnecessary MASLD referrals
    Jun-Hyuk Lee, Eileen Laurel Yoon, Ju Hyun Oh, Kyunam Kim, Sang Bong Ahn, Dae Won Jun
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes
    Merve Cebi, Yusuf Yilmaz
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    The Korean Journal of Medicine.2024; 99(4): 189.     CrossRef
  • Agile 3+ and Agile 4 scores predict chronic kidney disease development in metabolic dysfunction‐associated steatotic liver disease
    Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim
    Alimentary Pharmacology & Therapeutics.2024; 60(8): 1051.     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    Gut and Liver.2024; 18(5): 924.     CrossRef
  • A new Korean nomenclature for steatotic liver disease

    Clinical and Molecular Hepatology.2024; 30(Suppl): S214.     CrossRef
  • Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
    Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim
    Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1599.     CrossRef
  • Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification
    Min Kyu Kang, Jeong Eun Song, Rohit Loomba, Soo Young Park, Won Young Tak, Young Oh Kweon, Yu Rim Lee, Jung Gil Park
    Scientific Reports.2024;[Epub]     CrossRef
  • A narrative review of lifestyle management guidelines for metabolic dysfunction–associated steatotic liver disease
    Dana Ivancovsky Wajcman, Christopher J. Byrne, John F. Dillon, Paul N. Brennan, Marcela Villota-Rivas, Zobair M. Younossi, Alina M. Allen, Javier Crespo, Lynn H. Gerber, Jeffrey V. Lazarus
    Hepatology.2024;[Epub]     CrossRef
  • Visceral Obesity and Its Association with Severe Coronary Artery Calcification in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
    Min Kyu Kang, Jeung Eun Song, Young Oh Kweon, Won Young Tak, Soo Young Park, Yu Rim Lee, Jung Gil Park
    Diagnostics.2024; 14(20): 2305.     CrossRef
  • Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review
    Han Ah Lee
    The Ewha Medical Journal.2024;[Epub]     CrossRef
  • Evaluation of hepatoprotective and nephroprotective activities of Castanopsis costata extract in rats
    Maulana Alkandahri, Asman Sadino, Ermi Abriyani, Faizal Hermanto, Zulpakor Oktoba, Muhammad Sayoeti, Putu Sangging, Diah Wardani, Nahrul Hasan, Suci Sari, Nurul Safitri, Windi Ikhtianingsih, Safitri Safitri
    Biomedical Reports.2024;[Epub]     CrossRef
  • Cross-talk between gut microbiota and liver steatosis: Complications and therapeutic target
    Yuan Yao, Yunfeng Shen
    Open Life Sciences.2023;[Epub]     CrossRef
  • Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease
    Ho Soo Chun, Minjong Lee, Hye Ah Lee, Seo Yeong Oh, Hyo Jeong Baek, Jae Won Moon, Yeon Jeong Kim, Jinha Lee, Hyoeun Kim, Hwi Young Kim, Kwon Yoo, Tae Hun Kim, Seung Up Kim
    Clinical Gastroenterology and Hepatology.2023; 21(2): 358.     CrossRef
  • Non-Invasive Liver Fibrosis Scores Are Associated With Contrast-Associated Acute Kidney Injury in Patients Undergoing Elective Percutaneous Coronary Intervention
    Hao-Ming He, Chen He, Zhe-Bin You, Si-Cheng Zhang, Xue-Qin Lin, Man-Qing Luo, Mao-Qing Lin, Li-Wei Zhang, Kai-Yang Lin, Yan-Song Guo
    Angiology.2023; 74(4): 333.     CrossRef
  • Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome
    Dong Hyun Sinn, Danbee Kang, Sung Chul Choi, Yun Soo Hong, Di Zhao, Eliseo Guallar, Yewan Park, Juhee Cho, Geum-Youn Gwak
    Clinical Gastroenterology and Hepatology.2023; 21(7): 1873.     CrossRef
  • The association of non‐alcoholic fatty liver disease between parents and adolescent children
    Yewan Park, Dong Hyun Sinn, Kyunga Kim, Geum‐Youn Gwak
    Alimentary Pharmacology & Therapeutics.2023; 57(2): 245.     CrossRef
  • Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
    European Journal of Clinical Investigation.2023;[Epub]     CrossRef
  • Reply
    Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak
    Clinical Gastroenterology and Hepatology.2023; 21(9): 2435.     CrossRef
  • Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma
    Yoon-a Hwang, Hye Won Lee, Sang Hoon Ahn, Eun Jig Lee, Cheol Ryong Ku, Seung Up Kim
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Ideal cardiovascular health metrics and the risk of nonalcoholic fatty liver disease in Korean adults
    Sun Young Shim, Sun Jae Jung, Seung Up Kim, Hyeon Chang Kim
    Clinical Hypertension.2023;[Epub]     CrossRef
  • Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease”
    Won Sohn, Yong-Han Paik
    Clinical and Molecular Hepatology.2023; 29(1): 182.     CrossRef
  • Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”
    Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
    Clinical and Molecular Hepatology.2023; 29(1): 185.     CrossRef
  • Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
    Seung Min Lee, Dae Won Jun
    Clinical and Molecular Hepatology.2023; 29(1): 171.     CrossRef
  • Correspondence on Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”
    Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
    Clinical and Molecular Hepatology.2023; 29(1): 179.     CrossRef
  • Recurrence of hepatocellular carcinoma in noncirrhotic patients with nonalcoholic fatty liver disease versus hepatitis B infection
    Jungnam Lee, Jong-In Chang, Young-Joo Jin, Jeong-Hoon Lee, Ju Yeon Kim, Dong Hyun Sinn, Soon Sun Kim, Hyun Woong Lee, Sun Hong Yoo, Jung Hwan Yu, Jin-Woo Lee
    European Journal of Gastroenterology & Hepatology.2023; 35(4): 431.     CrossRef
  • Comparison of Guidelines for the Screening, Diagnosis, and Noninvasive Assessment of Nonalcoholic Fatty Liver Disease
    Kenneth W. Chow, Pragyat Futela, Aryan Saharan, Sammy Saab
    Journal of Clinical and Experimental Hepatology.2023; 13(5): 783.     CrossRef
  • Clinical Implications of Cardiac Symptoms and Electrocardiographic Abnormalities for Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
    Min-Kyu Kang, Min-Cheol Kim
    Medicina.2023; 59(2): 375.     CrossRef
  • The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review
    George Chen, Bubu Banini, Albert Do, Joseph K. Lim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S319.     CrossRef
  • Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma
    Yuri Cho, Bo Hyun Kim, Joong-Won Park
    Clinical and Molecular Hepatology.2023; 29(Suppl): S220.     CrossRef
  • Global incidence and prevalence of nonalcoholic fatty liver disease
    Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah
    Clinical and Molecular Hepatology.2023; 29(Suppl): S32.     CrossRef
  • Non-alcoholic fatty liver disease: the pathologist’s perspective
    Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S302.     CrossRef
  • Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models
    Dong Yun Kim, Kyu Sik Chung, Jun Yong Park, Heon Yung Gee
    Biomedicine & Pharmacotherapy.2023; 161: 114445.     CrossRef
  • Effects of additive interactions among obesity, visceral adiposity, and sarcopenia on nonalcoholic fatty liver disease
    Goh Eun Chung, Sohee Oh, Dong-Won Ahn, Su Hwan Kim, Yong Jin Jung, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, Ji Bong Jeong
    Scientific Reports.2023;[Epub]     CrossRef
  • Screening strategy for non-alcoholic fatty liver disease
    Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto
    Clinical and Molecular Hepatology.2023; 29(Suppl): S103.     CrossRef
  • Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
    Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne
    Clinical and Molecular Hepatology.2023; 29(Suppl): S157.     CrossRef
  • Baseline Tyrosine Level Is Associated with Dynamic Changes in FAST Score in NAFLD Patients under Lifestyle Modification
    Hwi Young Kim, Da Jung Kim, Hye Ah Lee, Joo-Youn Cho, Won Kim
    Metabolites.2023; 13(3): 444.     CrossRef
  • Nonalcoholic fatty liver disease and non-liver comorbidities
    Richie Manikat, Mindie H. Nguyen
    Clinical and Molecular Hepatology.2023; 29(Suppl): s86.     CrossRef
  • Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
    Peter Konyn, Aijaz Ahmed, Donghee Kim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S43.     CrossRef
  • Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
    Jihyun An, Joo Hyun Sohn
    Clinical and Molecular Hepatology.2023; 29(Suppl): S268.     CrossRef
  • Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
    Sang Bong Ahn
    Clinical and Molecular Hepatology.2023; 29(Suppl): S150.     CrossRef
  • Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
    Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima
    Clinical and Molecular Hepatology.2023; 29(Suppl): S123.     CrossRef
  • Comparison between obese and non-obese nonalcoholic fatty liver disease
    Wah-Kheong Chan
    Clinical and Molecular Hepatology.2023; 29(Suppl): S58.     CrossRef
  • Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
    Jung Hwan Yu, Han Ah Lee, Seung Up Kim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S136.     CrossRef
  • Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease
    Georg Semmler, Christian Datz, Michael Trauner
    Clinical and Molecular Hepatology.2023; 29(Suppl): S244.     CrossRef
  • Non-alcoholic fatty liver disease: Definition and subtypes
    Seul Ki Han, Soon Koo Baik, Moon Young Kim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S5.     CrossRef
  • The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
    Hyunwoo Oh, Won Sohn, Yong Kyun Cho
    Clinical and Molecular Hepatology.2023; 29(Suppl): S261.     CrossRef
  • Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
    Yi-wen Shi, Jian-Gao Fan
    Clinical and Molecular Hepatology.2023; 29(Suppl): S228.     CrossRef
  • Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management
    Anja Geerts, Sander Lefere
    Clinical and Molecular Hepatology.2023; 29(Suppl): S276.     CrossRef
  • Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
    Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra
    Clinical and Molecular Hepatology.2023; 29(Suppl): S286.     CrossRef
  • CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease
    Ha Neul Kim, Hong Jae Jeon, Hei Gwon Choi, In Sun Kwon, Woo Sun Rou, Jeong Eun Lee, Tae Hee Lee, Seok Hyun Kim, Byung Seok Lee, Kyung Sook Shin, Hyun Jung Lee, Hyuk Soo Eun
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • How many times should we repeat measurements of the ultrasound-guided attenuation parameter for evaluating hepatic steatosis?
    Duck Min Seo, Sang Min Lee, Ji Won Park, Min-Jeong Kim, Hong Il Ha, Sun-Young Park, Kwanseop Lee
    Ultrasonography.2023; 42(2): 227.     CrossRef
  • The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review
    Young-Joo Jin
    Clinical and Molecular Hepatology.2023; 29(2): 414.     CrossRef
  • Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
    Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang
    Clinical and Molecular Hepatology.2023; 29(2): 404.     CrossRef
  • The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
    Ji-Won Park, Ki Tae Suk
    Clinical and Molecular Hepatology.2023; 29(2): 408.     CrossRef
  • Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
    Philipp Kasper, Münevver Demir, Hans-Michael Steffen
    Clinical and Molecular Hepatology.2023; 29(2): 390.     CrossRef
  • Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study
    Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith
    Clinical and Molecular Hepatology.2023; 29(2): 433.     CrossRef
  • The growing burden of non-alcoholic fatty liver disease on mortality
    Ju-Yeon Cho, Won Sohn
    Clinical and Molecular Hepatology.2023; 29(2): 374.     CrossRef
  • Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease
    Min Kyu Kang, Yu Rim Lee, Se Young Jang, Won Young Tak, Young Oh Kweon, Jeong Eun Song, Rohit Loomba, Soo Young Park, Jung Gil Park
    Hepatology International.2023; 17(3): 626.     CrossRef
  • Genetic association study identifies genetic variants for non-alcoholic fatty liver without comorbidities in the Korean population
    Yeon Jun Kim, Yoon Shin Cho
    Genes & Genomics.2023; 45(7): 847.     CrossRef
  • Association between the fatty liver index and the risk of fracture among individuals over the age of 50 years: a nationwide population-based study
    Goh Eun Chung, Eun Ju Cho, Min Joo Kim, Jeong-Ju Yoo, Yuri Cho, Kyu-na Lee, Kyungdo Han, Yoon Jun Kim, Jung-Hwan Yoon, Dong Wook Shin, Su Jong Yu
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease
    Han Ah Lee, Hwi Young Kim
    International Journal of Molecular Sciences.2023; 24(11): 9324.     CrossRef
  • Low‐quality muscle mass rather than normal‐quality muscle mass determines fibrosis progression in biopsy‐proven NAFLD
    Yun Kyu Lee, Bo Kyung Koo, Sae Kyung Joo, Dong Hyeon Lee, Heejoon Jang, Jee Won Chai, Myoung Seok Lee, Si Won Jang, Young Ho So, Jeong Hwan Park, Mee Soo Chang, Won Kim
    Alimentary Pharmacology & Therapeutics.2023; 58(3): 322.     CrossRef
  • Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD
    Beom K. Kim, Nicole Bernstein, Daniel Q. Huang, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajim
    Alimentary Pharmacology & Therapeutics.2023; 58(2): 229.     CrossRef
  • Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study
    Heejin Cho, Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, Seong Gyu Hwang
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
    Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik
    JHEP Reports.2023; 5(9): 100810.     CrossRef
  • Transient elastography with controlled attenuation parameter versus two-dimensional shear wave elastography with attenuation imaging for the evaluation of hepatic steatosis and fibrosis in NAFLD
    Jung Wook Seo, Youe Ree Kim, Jong Keon Jang, So Yeon Kim, Young Youn Cho, Eun Sun Lee, Dong Ho Lee
    Ultrasonography.2023; 42(3): 421.     CrossRef
  • Serum resistin and the risk for hepatocellular carcinoma in diabetic patients
    Mona Mohamed Ibrahim Abdalla
    World Journal of Gastroenterology.2023; 29(27): 4271.     CrossRef
  • Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes
    Tae Seop Lim, Ho Soo Chun, Soon Sun Kim, Ja Kyung Kim, Minjong Lee, Hyo Jung Cho, Seung Up Kim, Jae Youn Cheong
    Gut and Liver.2023; 17(4): 610.     CrossRef
  • The correlation between NAFLD and serum uric acid to serum creatinine ratio
    Jangwon Choi, Hyun Joe, Jung-Eun Oh, Yong-Jin Cho, Hwang-Sik Shin, Nam Hun Heo, Gulali Aktas
    PLOS ONE.2023; 18(7): e0288666.     CrossRef
  • Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non‐cirrhotic patients with chronic hepatitis B
    Cheol‐Hyung Lee, Yun Bin Lee, Hyemi Moon, Jong‐Won Chung, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Juneyoung Lee, Jung‐Hwan Yoon
    Alimentary Pharmacology & Therapeutics.2023; 58(7): 704.     CrossRef
  • Aerobic and Resistance Exercise: Synergistic Influence for Nonalcoholic Fatty Liver Disease
    Ho Soo Chun
    Gut and Liver.2023; 17(4): 485.     CrossRef
  • KASL clinical practice guidelines for management of autoimmune hepatitis 2022

    Clinical and Molecular Hepatology.2023; 29(3): 542.     CrossRef
  • Comments on Relationship between the High Fatty Liver Index and Risk of Fracture: Reply
    Min-Ji Kim, Jae-Hyung Roh, Jae-Han Jeon
    Gut and Liver.2023; 17(4): 663.     CrossRef
  • Regression of nonalcoholic fatty liver disease is associated with reduced risk of incident diabetes: A longitudinal cohort study
    Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Sung Chul Choi, Yun Soo Hong, Yewan Park, Juhee Cho, Geum-Youn Gwak, Ahmed Mustafa Rashid
    PLOS ONE.2023; 18(7): e0288820.     CrossRef
  • Effect of 12-week intermittent calorie restriction compared to standard of care in patients with nonalcoholic fatty liver disease: a randomized controlled trial
    Han Ah Lee, Hyeyoung Moon, Yuri Kim, Hye Ah Lee, Hwi Young Kim
    Trials.2023;[Epub]     CrossRef
  • Associations of Serum Uric Acid Level With Liver Enzymes, Nonalcoholic Fatty Liver Disease, and Liver Fibrosis in Korean Men and Women: A Cross-Sectional Study Using Nationally Representative Data
    Jun Myong Lee, Hye Won Kim, So Young Heo, Kyung Yi Do, Jun Deok Lee, Seul Ki Han, Soon Koo Baik, Moon Young Kim, Sei-Jin Chang
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Statins for treatment of fatty liver disease: Recent advances
    Xiao-Hui Fang, Cai-E Wang, Jiao Deng, Xing-Shun Qi
    World Chinese Journal of Digestology.2023; 31(16): 659.     CrossRef
  • MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study
    Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim
    Journal of Gastroenterology and Hepatology.2023; 38(9): 1598.     CrossRef
  • The effect of hepatic steatosis on 18F-FDG uptake in PET-CT examinations of cancer Egyptian patients
    Magdi A. Ali, Eman El-Abd, Mohamed Morsi, Mohamed M. El Safwany, Mohamed Z. El-Sayed
    European Journal of Hybrid Imaging.2023;[Epub]     CrossRef
  • Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
    Gi-Ae Kim, Joon Ho Moon, Won Kim
    Clinical and Molecular Hepatology.2023; 29(4): 831.     CrossRef
  • Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea
    Yuri Cho, SeongBeom Park, SeonYoung Park, WonJung Choi, Book Kim, Helin Han
    Infectious Diseases and Therapy.2023; 12(10): 2387.     CrossRef
  • Association between waist circumference trajectories and incident non-alcoholic fatty liver disease
    Jun-Hyuk Lee, Soyoung Jeon, Hye Sun Lee, Yu-Jin Kwon
    Obesity Research & Clinical Practice.2023; 17(5): 398.     CrossRef
  • Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention
    Tianyu Mao, Yiwen Sun, Xinyi Xu, Kang He
    Hepatology Communications.2023;[Epub]     CrossRef
  • Approach to Fatty Liver Disease in Patients with Type 2 Diabetes
    Ji Cheol Bae
    The Journal of Korean Diabetes.2023; 24(3): 107.     CrossRef
  • Lactobacillus plantarum ameliorates NASH-related inflammation by upregulating l-arginine production
    Dong Yun Kim, Jun Yong Park, Heon Yung Gee
    Experimental & Molecular Medicine.2023; 55(11): 2332.     CrossRef
  • Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study
    Beom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramazan Idilman, Mesut Gumussoy, Digdem K. Oz, Ayse Erden, Emily Truong, Ju Dong Yang, Mazen Noureddin, Alina M. Allen, Rohit Loomba, Veeral Ajmera
    Hepatology.2023; 78(6): 1858.     CrossRef
  • Association between total body muscle percentage and prevalence of non-alcoholic fatty liver disease in Korean adults findings from an 18-year follow-up: a prospective cohort study
    Byoung Chan Ahn, Chul Yong Park, Jung Hee Hong, Ki Ook Baek
    Journal of Yeungnam Medical Science.2023; 40(Suppl): S47.     CrossRef
  • The Association of Perfluoroalkyl Substance Exposure and a Serum Liver Function Marker in Korean Adults
    Jisuk Yun, Soon-Chan Kwon
    Toxics.2023; 11(12): 965.     CrossRef
  • Alcohol consumption and the risk of liver disease: a nationwide, population-based study
    Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Lifestyle of patients with non-alcoholic fatty liver disease: assessment of dietary habits and physical activity
    T.S. Krolevets, M.I. Syrovenko, M.A. Livzan
    Russian Journal of Evidence-Based Gastroenterology.2023; 12(4): 43.     CrossRef
  • Association of Hepatic Fat Deposition and Severity of Acanthosis Nigricans in Children and Adolescents with Obesity
    Junhyung Lee, Hye-ji An, Young-Gyun Seo, Hong Ji Song, Hye-Mi Noh, Yu-Jin Paek, Kyung Hee Park
    Korean Journal of Family Practice.2023; 13(4): 240.     CrossRef
  • Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease
    Chan-Young Jung, Geun Woo Ryu, Hyung Woo Kim, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim
    Diabetologia.2022; 65(3): 518.     CrossRef
  • Long-term effects of the changes in hepatic steatosis status on the risk of incident type 2 diabetes mellitus: A 15-year community-based prospective cohort study
    Seung Min Chung, Min Kyu Kang, Jinho Jung, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee, Rohit Loomba, Jung Gil Park, Jun Sung Moon
    Diabetes Research and Clinical Practice.2022; 184: 109208.     CrossRef
  • Benefit of Antiviral Therapy for HBV-Related HCC with Undetectable HBV DNA Is Still Dubious
    Suprabhat Giri, Harish Darak, Sunil Kasturi
    Digestive Diseases and Sciences.2022; 67(10): 4962.     CrossRef
  • Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role
    Haripriya Gupta, Byeong-Hyun Min, Raja Ganesan, Yoseph Asmelash Gebru, Satya Priya Sharma, Eunju Park, Sung-Min Won, Jin-Ju Jeong, Su-Been Lee, Min-Gi Cha, Goo-Hyun Kwon, Min-Kyo Jeong, Ji-Ye Hyun, Jung-A. Eom, Hee-Jin Park, Sang-Jun Yoon, Mi-Ran Choi, Do
    Biomedicines.2022; 10(3): 550.     CrossRef
  • Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis
    Heejoon Jang, Yun Bin Lee, Hyemi Moon, Jong‐Won Chung, Joon Yeul Nam, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Juneyoung Lee, Jung‐Hwan Yoon
    Hepatology.2022; 76(2): 492.     CrossRef
  • The Phase 2 Study to Evaluate Efficacy and Safety of Lanifibranor in Patients with Nonalcoholic Steatohepatitis: Back in the Spotlight?
    Sae Hwan Lee
    The Korean Journal of Gastroenterology.2022; 79(3): 138.     CrossRef
  • Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study
    Chan-Young Jung, Hee Byung Koh, Keun Hyung Park, Young Su Joo, Hyung Woo Kim, Sang Hoon Ahn, Jung Tak Park, Seung Up Kim
    Diabetes & Metabolism.2022; 48(4): 101344.     CrossRef
  • MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
    Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
    Clinical and Molecular Hepatology.2022; 28(2): 150.     CrossRef
  • PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
    Naomi F. Lange, Vanessa Graf, Cyrielle Caussy, Jean-François Dufour
    International Journal of Molecular Sciences.2022; 23(8): 4305.     CrossRef
  • Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study
    Jaejun Lee, Taeyun Kim, Hyun Yang, Si Hyun Bae
    Clinical and Molecular Hepatology.2022; 28(2): 196.     CrossRef
  • Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease
    Youn Huh, Yoon Jeong Cho, Ga Eun Nam
    Journal of Obesity & Metabolic Syndrome.2022; 31(1): 17.     CrossRef
  • Gamma‐glutamyl transpeptidase dynamics as a biomarker for advanced fibrosis in non‐alcoholic fatty liver disease
    Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Seong Gyu Hwang
    Journal of Gastroenterology and Hepatology.2022; 37(8): 1624.     CrossRef
  • The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study
    Yuri Cho, Eun Ju Cho, Jeong-Ju Yoo, Young Chang, Goh Eun Chung, In Young Choi, Sang-Hyun Park, Kyungdo Han, Yoon Jun Kim, Jung-Hwan Yoon, Dong Wook Shin, Su Jong Yu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Association of Low Skeletal Muscle Mass with the Phenotype of Lean Non-Alcoholic Fatty Liver Disease
    Jun-Hyeon Byeon, Min-Kyu Kang, Min-Cheol Kim
    Healthcare.2022; 10(5): 850.     CrossRef
  • Association of Metabolomic Change and Treatment Response in Patients with Non-Alcoholic Fatty Liver Disease
    Kwang Seob Lee, Yongin Cho, Hongkyung Kim, Hyunkyeong Hwang, Jin Won Cho, Yong-ho Lee, Sang-Guk Lee
    Biomedicines.2022; 10(6): 1216.     CrossRef
  • Risk of liver fibrosis in patients with prediabetes and diabetes mellitus
    Jongsin Park, Heon-Ju Kwon, Won Sohn, Ju-Yeon Cho, Soo Jin Park, Yoosoo Chang, Seungho Ryu, Byung Ik Kim, Yong Kyun Cho, Chen-Hua Liu
    PLOS ONE.2022; 17(6): e0269070.     CrossRef
  • Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: A nationwide cohort study
    Chan-Young Jung, Ho Soo Chun, Minjong Lee, Hee Byung Koh, Keun Hyung Park, Young Su Joo, Hyung Woo Kim, Sang Hoon Ahn, Jung Tak Park, Seung Up Kim
    Diabetes & Metabolism.2022; 48(5): 101362.     CrossRef
  • Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study
    Dong Hyun Sinn, Danbee Kang, Mira Kang, Eliseo Guallar, Yun Soo Hong, Kyung Hyun Lee, Jiyeon Park, Juhee Cho, Geum‐Youn Gwak
    Hepatology.2022; 76(6): 1746.     CrossRef
  • Short-term outcome of bariatric surgery on nonalcoholic fatty liver disease: a Korean perspective
    Ki Hyun Kim, Yoonhong Kim, Kwang Il Seo, Kyung Won Seo
    Annals of Surgical Treatment and Research.2022; 102(6): 353.     CrossRef
  • A Case Report of Nonalcoholic Fatty Liver Disease with Obesity and Dyslipidemia
    Eujin Kim, Cho-Hyun Hwang, Juyoung Lee, Eungyeong Jang, Youngchul Kim, Jang-Hoon Lee
    The Journal of Internal Korean Medicine.2022; 43(2): 184.     CrossRef
  • Lean non-alcoholic fatty liver disease (Lean-NAFLD) and the development of metabolic syndrome: a retrospective study
    Wenting Wang, Jianping Ren, Wenzhao Zhou, Jinyu Huang, Guomin Wu, Fenfang Yang, Shuang Yuan, Juan Fang, Jing Liu, Yao Jin, Haiyang Qi, Yuyang Miao, Yanna Le, Cenhong Ge, Xiantao Qiu, JinJing Wang, Ping Huang, Zixin Liu, Sheng Wang
    Scientific Reports.2022;[Epub]     CrossRef
  • Obstructive Sleep Apnea and Nonalcoholic Fatty Liver Disease in the General Population: A Cross-Sectional Study Using Nationally Representative Data
    Taeyun Kim, Hyunji Choi, Jaejun Lee, Jehun Kim
    International Journal of Environmental Research and Public Health.2022; 19(14): 8398.     CrossRef
  • Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions
    Jung Il Lee
    Gut and Liver.2022; 16(4): 497.     CrossRef
  • Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
    Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
    Clinical and Molecular Hepatology.2022; 28(3): 425.     CrossRef
  • Real‐world clinical features, health‐care utilization, and economic burden in decompensated cirrhosis patients: A national database
    Hankil Lee, Beom Kyung Kim
    Journal of Gastroenterology and Hepatology.2022; 37(11): 2154.     CrossRef
  • Reply
    Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Juhee Cho, Geum‐Youn Gwak
    Hepatology.2022; 76(6): E121.     CrossRef
  • Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD
    Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Tuo Lin, Xin M. Tu, Jaclyn Bergstrom, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi N
    Journal of Hepatology.2022; 77(6): 1482.     CrossRef
  • Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease
    Han Ah Lee, Seung-seob Kim, Jin-Young Choi, Yeon Seok Seo, Beom Jin Park, Ki Choon Sim, Seung Up Kim
    Abdominal Radiology.2022; 47(11): 3733.     CrossRef
  • Fatty Liver Change in Korean Adults in a Systematic Social Distancing System Amid the COVID-19 Pandemic: A Multicenter Analysis
    Ji-Hee Haam, Yang-Im Hur, Young-Sang Kim, Kyoung-Kon Kim, Jee-Hyun Kang, Hae-Jin Ko, Yoon Jeong Cho, Hye-In Choi, Kyu Rae Lee, Jung Ha Park, Soo Hyun Cho, Jong-Koo Kim, Taesic Lee, Myung-Jae Seo, Yeong Sook Yoon, Yoobin Seo, Ga Eun Nam, Sun Hyun Kim
    International Journal of Environmental Research and Public Health.2022; 19(16): 10444.     CrossRef
  • Association between grip strength and non-alcoholic fatty liver disease: A systematic review and meta-analysis
    Liu Han, Shifeng Fu, Jianglei Li, Deliang Liu, Yuyong Tan
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Correlation between shift work and non-alcoholic fatty liver disease among male workers in the steel manufacturing company of Korea: a cross-sectional study
    Kiseok Kim, Yong-Jin Lee, Soon-Chan Kwon, Young-Sun Min, Hyun Kyo Lee, Gwangin Baek, Sang Hyeon Kim, Eun-Chul Jang
    Annals of Occupational and Environmental Medicine.2022;[Epub]     CrossRef
  • Radiomics Analysis of Magnetic Resonance Proton Density Fat Fraction for the Diagnosis of Hepatic Steatosis in Patients With Suspected Non-Alcoholic Fatty Liver Disease
    Ki Choon Sim, Min Ju Kim, Yongwon Cho, Hyun Jin Kim, Beom Jin Park, Deuk Jae Sung, Na Yeon Han, Yeo Eun Han, Tae Hyung Kim, Yoo Jin Lee
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Bioelectrical Impedance Analysis Can Be an Effective Tool for Screening Fatty Liver in Patients with Suspected Liver Disease
    Jin Wook Choi, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
    Healthcare.2022; 10(11): 2268.     CrossRef
  • Tenofovir alafenamide alleviates nonalcoholic steatohepatitis in mice by blocking the phosphorylation of AKT in intrahepatic mononuclear phagocytes
    Pu Reun Roh, Sung Min Kim, Byung-Yoon Kang, Kyoung Do Mun, Jong Geun Park, Min Woo Kang, Wonhee Hur, Ji Won Han, Heechul Nam, Seung Kew Yoon, Pil Soo Sung
    Biomedicine & Pharmacotherapy.2022; 156: 113952.     CrossRef
  • Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Sangsoo Han, Miyoung Choi, Bora Lee, Hye-Won Lee, Seong Hee Kang, Yuri Cho, Sang Bong Ahn, Do Seon Song, Dae Won Jun, Jieun Lee, Jeong-Ju Yoo
    Gut and Liver.2022; 16(6): 952.     CrossRef
  • The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults
    Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
    Clinical and Molecular Hepatology.2022; 28(4): 814.     CrossRef
  • Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations
    Soon Sun Kim, Jae Youn Cheong
    Clinical and Molecular Hepatology.2022; 28(4): 802.     CrossRef
  • Association between small dense LDL levels and hepatic fibrosis in patients with nonalcoholic fatty liver disease
    Sun Young Kim, Subin Mun, Jung Hwan Yu, Young-Joo Jin, Young Ju Suh, Sang-Heon Cho, Jin-Woo Lee
    Medicine.2022; 101(37): e30527.     CrossRef
  • A Review of Research Trends in Traditional Korean Medicine for Nonalcoholic Fatty Liver Disease
    Na-yeon Kim, Mi-jung Yoon, Hong-sik Choi, Seung-mo Kim, Sang-chan Kim, Kyung-soon Kim
    The Journal of Internal Korean Medicine.2022; 43(4): 680.     CrossRef
  • Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies
    Seogsong Jeong, Won Kim, Sang Min Park
    Clinical and Molecular Hepatology.2022; 28(4): 933.     CrossRef
  • Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis
    Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim
    Diagnostics.2022; 13(1): 3.     CrossRef
  • Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy
    Pengyu Yao, Yajuan Liu
    Molecules.2022; 28(1): 272.     CrossRef
  • The Evidence Surrounding Non-Alcoholic Fatty Liver Disease in Individuals with Cancer: A Systematic Literature Review
    Elena S. George, Surbhi Sood, Nicole Kiss, Robin M. Daly, Amanda J. Nicoll, Stuart K. Roberts, Brenton J. Baguley
    Current Oncology.2022; 30(1): 48.     CrossRef
  • Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Korean Patients Undergoing Bariatric Surgery
    Ki Hyun Kim, Yoonhong Kim, Kwang Il Seo, Kyung Won Seo
    Journal of Metabolic and Bariatric Surgery.2022; 11(2): 63.     CrossRef
  • Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population
    Eun-Ju Cho, Gu-Cheol Jung, Min-Sun Kwak, Jong-In Yang, Jeong-Yoon Yim, Su-Jong Yu, Goh-Eun Chung
    Diagnostics.2021; 11(12): 2233.     CrossRef
  • Association between Fasting Ketonuria and Advanced Liver Fibrosis in Non-Alcoholic Fatty Liver Disease Patients without Prediabetes and Diabetes Mellitus
    Kiyoung Lim, Minkyu Kang, Junggil Park
    Nutrients.2021; 13(10): 3400.     CrossRef
  • Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression
    Jeong-An Gim, Soo Min Bang, Young-Sun Lee, Yoonseok Lee, Sun Young Yim, Young Kul Jung, Hayeon Kim, Baek-Hui Kim, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun, Matias A. Avila
    PLOS ONE.2021; 16(8): e0255822.     CrossRef
  • Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Effect of Nutrition Education in NAFLD Patients Undergoing Simultaneous Hyperlipidemia Pharmacotherapy: A Randomized Controlled Trial
    Won Myung Lee, Jea Hurn Bae, Young Chang, Sae Hwan Lee, Ji Eun Moon, Soung Won Jeong, Jae Young Jang, Sang Gyune Kim, Hong Soo Kim, Jeong-Ju Yoo, Young Seok Kim
    Nutrients.2021; 13(12): 4453.     CrossRef
  • Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
    Jae Seung Lee, Dong Hyun Sinn, Soo Young Park, Hye Jung Shin, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Joo Hyun Oh, Jung Il Lee, Seung Up Kim
    Cancers.2021; 13(18): 4567.     CrossRef
  • 32,514 View
  • 1,305 Download
  • 197 Web of Science
  • Crossref
Original Articles

Viral hepatitis

Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
Young Min Kim, Suk Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae, Myeong Jun Song, Ji Woong Jang, Soon Young Ko, Jae Dong Lee
Clin Mol Hepatol 2018;24(3):311-318.
Published online June 4, 2018
DOI: https://doi.org/10.3350/cmh.2017.0070
Background/Aims
Sofosbuvir plus ribavirin is a standard treatment for patients infected with chronic hepatitis C virus (HCV) genotype 2 in Korea. The purpose of this study was to examine the efficacy and safety of this treatment in Korean patients with chronic HCV genotype 2 infection.
Methods
We retrospectively analyzed clinical data of patients treated with sofosbuvir plus ribavirin for chronic HCV genotype 2 from May 2016 to December 2017 at eight hospitals located in the Daejeon-Chungcheong area.
Results
A total of 172 patients were treated with sofosbuvir plus ribavirin. Of them, 163 patients completed the treatment, and 162 patients were tested for sustained virologic response 12 weeks after treatment discontinuation (SVR12). Mean age was 59.6±12.3 years (27–96), and 105 (64.4%) patients were female. Of the total patients, 49 (30.1%) were diagnosed with cirrhosis, and 31 of them were treated for 16 weeks. Sofosbuvir plus ribavirin was the first-line treatment for 144 (88.3%) patients. Eleven (6.7%) patients were intolerant to previous interferon-based treatment. Eight (5.0%) patients relapsed after interferon-based treatment. HCV RNA non-detection rate at 4, 8, and 12 weeks was 97.5%, 99.1%, and 99.3%, respectively, and SVR12 was 98.8% (161/163). During treatment, 18 (11.0%) patients had to reduce their administrated dose of ribavirin because of anemia. One patient stopped the treatment because of severe anemia. Other adverse events, including dizziness, indigestion, and headache, were found in 26 (16.0%) patients.
Conclusions
A 12-16 week treatment with sofosbuvir plus ribavirin is remarkably effective and well tolerated in Korean patients with chronic HCV genotype 2 infection.

Citations

Citations to this article as recorded by  Crossref logo
  • Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study
    Ik Sung Choi, Kwang Min Kim, Sang Goon Shim
    Arab Journal of Gastroenterology.2021; 22(1): 23.     CrossRef
  • Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution
    Young Joo Park, Hyun Young Woo, Jeong Heo, Sang Gyu Park, Young Mi Hong, Ki Tae Yoon, Dong Uk Kim, Gwang Ha Kim, Hyung Hoi Kim, Geun Am Song, Mong Cho
    Gut and Liver.2021; 15(3): 440.     CrossRef
  • Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose
    Carlo Smirne, Antonio D'Avolio, Mattia Bellan, Alessandro Gualerzi, Maria G. Crobu, Mario Pirisi
    Pharmacology Research & Perspectives.2021;[Epub]     CrossRef
  • Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment
    Jennifer J. Lin, Catrina M. Loucks, Jessica N. Trueman, Britt I. Drögemöller, Galen E.B. Wright, Eric M. Yoshida, Jo-Ann Ford, Samuel S. Lee, Richard B. Kim, Bandar Al-Judaibi, Ute I. Schwarz, Alnoor Ramji, Edward Tam, Colin J. Ross, Bruce C. Carleton
    Biomedicine & Pharmacotherapy.2021; 143: 112195.     CrossRef
  • Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin
    Chi-Ching Chen, Shui-Yi Tung, Kuo-Liang Wei, Chien-Heng Shen, Te-Sheng Chang, Wei-Ming Chen, Huang-Wei Xu, Chih-Wei Yen, Yi-Hsing Chen, Sheng-Nan Lu, Chao-Hung Hung
    Journal of the Formosan Medical Association.2020; 119(1): 532.     CrossRef
  • Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
    Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2020; 12(11): 3414.     CrossRef
  • Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose
    Eun Sun Jang, Kyung-Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook-Hyang Jeong
    Gut and Liver.2020; 14(6): 775.     CrossRef
  • Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium
    Chung-Feng Huang, Etsuko Iio, Dae Won Jun, Eiichi Ogawa, Hidenori Toyoda, Yao-Chun Hsu, Hiroaki Haga, Shinji Iwane, Masaru Enomoto, Dong Hyun Lee, Grace Wong, Chen-Hua Liu, Toshifumi Tada, Wan-Long Chuang, Ramsey Cheung, Jun Hayashi, Cheng-Hao Tseng, Sato
    Hepatology International.2019; 13(5): 587.     CrossRef
  • Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea
    Young-Hwan Ahn, Hyungcheol Park, Myeon Jae Lee, Dong Hyun Kim, Sung Bum Cho, Eunae Cho, Chung Hwan Jun, Sung Kyu Choi
    Gut and Liver.2019; 13(5): 549.     CrossRef
  • Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
    Jong Eun Yeon
    Clinical and Molecular Hepatology.2018; 24(3): 294.     CrossRef
  • Ribavirin/sofosbuvir

    Reactions Weekly.2018; 1727(1): 247.     CrossRef
  • 11,161 View
  • 206 Download
  • 11 Web of Science
  • Crossref

Viral hepatitis

Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
Byeong Wook Cho, Seok Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae
Clin Mol Hepatol 2017;23(1):51-56.
Published online March 16, 2017
DOI: https://doi.org/10.3350/cmh.2016.0053
Background/Aims
The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies. The purpose of this study was to clarify the results of treatment and side effects in Korean patients with chronic hepatitis C virus (HCV) genotype Ib infection.
Methods
We retrospectively analyzed clinical data from chronic HCV genotype Ib patients treated with DCV+ASV from August 2015 to September 2016 at five hospitals in the Daejeon-Chungcheong area.
Results
A total of 152 patients were examined for resistance associated variants (RAVs). Among them, 15 (9.9%) were positive for Y93 and one (0.7%) was positive for L31. Of 126 patients treated with DCV+ASV, 83 patients completed treatment and 76 patients were included in safety and efficacy analysis. Five (6.6%) were positive for Y93 and 12 (15.8%) exhibited cirrhotic change. DCV+ASV was the first-line treatment for 58 (76.3%) patients. Eleven (14.5%) patients relapsed after previous treatment that included interferon and seven (9.2%) of these patients were found to be intolerant of interferon. Adverse events occurred in 10 (13.2%) patients and two patients stopped the medication because of severe itching and skin rash. SVR12 was 89.5% (68/76) in all patients and 91.5% (65/71) in RAV-negative patients.
Conclusions
DCV+ASV showed good efficacy in patients with HCV Ib infection in Korea. Close monitoring is needed for severe adverse events and treatment failure, which were uncommon.

Citations

Citations to this article as recorded by  Crossref logo
  • The Incidence and Care Cascade of the Hepatitis C Virus in Korea
    Young Eun Chon, Aejeong Jo, Eileen L. Yoon, Jonghyun Lee, Ho Gyun Shin, Min Jung Ko, Dae Won Jun
    Gut and Liver.2023; 17(6): 926.     CrossRef
  • Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment
    Young-Hwan Ahn, Heirim Lee, Ji Eun Han, Hyo Jung Cho, Jae Youn Cheong, Bumhee Park, Soon Sun Kim
    Journal of Liver Cancer.2022; 22(2): 125.     CrossRef
  • Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea
    Jung Hyun Kwon, Sun Hong Yoo, Soon Woo Nam, Hee Yeon Kim, Chang Wook Kim, Chan Ran You, Sang Wook Choi, Se Hyun Cho, Joon‐Yeol Han, Do Seon Song, U Im Chang, Jin Mo Yang, Sung Won Lee, Hae Lim Lee, Nam Ik Han, Seok‐Hwan Kim, Myeong Jun Song, Pil Soo Sung,
    Journal of Medical Virology.2019; 91(6): 1104.     CrossRef
  • Discussion on critical points for a tailored therapy to cure hepatitis C virus infection
    Nadia Marascio, Angela Quirino, Giorgio Settimo Barreca, Luisa Galati, Chiara Costa, Vincenzo Pisani, Maria Mazzitelli, Giovanni Matera, Maria Carla Liberto, Alfredo Focà, Carlo Torti
    Clinical and Molecular Hepatology.2019; 25(1): 30.     CrossRef
  • Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis
    Byung Seok Lee, Myeong Jun Song, Jung Hyun Kwon, Tae Hee Lee, Ji Woong Jang, Seok Hyun Kim, Sae Hwan Lee, Hong Soo Kim, Ji Hoon Kim, Seok Bae Kim, Soon Young Ko, Do Seon Song
    Gut and Liver.2019; 13(2): 191.     CrossRef
  • Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
    Jae Young Oh, Byung Seok Kim, Chang Hyeong Lee, Jeong Eun Song, Heon Ju Lee, Jung Gil Park, Jae Seok Hwang, Woo Jin Chung, Byoung Kuk Jang, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Sang Gyu Kwak
    The Korean Journal of Internal Medicine.2019; 34(4): 794.     CrossRef
  • Real‐life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance‐associated substitution test
    Eun Sun Jang, Kyung‐Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook‐Hyang Jeong
    Journal of Medical Virology.2019; 91(12): 2158.     CrossRef
  • An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
    Youn Jae Lee, Jeong Heo, Do Young Kim, Woo Jin Chung, Won Young Tak, Yoon Jun Kim, Seung Woon Paik, Eungeol Sim, Susila Kulasingam, Rohit Talwani, Barbara Haber, Peggy Hwang
    Clinical and Molecular Hepatology.2019; 25(4): 400.     CrossRef
  • Systematic review with meta‐analysis: effectiveness and tolerability of interferon‐free direct‐acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia
    F. Ji, B. Wei, Y. H. Yeo, E. Ogawa, B. Zou, C. D. Stave, Z. Li, S. Dang, N. Furusyo, R. C. Cheung, M. H. Nguyen
    Alimentary Pharmacology & Therapeutics.2018; 47(5): 550.     CrossRef
  • Early development of de novo hepatocellular carcinoma after direct‐acting agent therapy: Comparison with pegylated interferon‐based therapy in chronic hepatitis C patients
    S. H. Yoo, J. H. Kwon, S. W. Nam, H. Y. Kim, C. W. Kim, C. R. You, S. W. Choi, S. H. Cho, J.‐Y. Han, D. S. Song, U. I. Chang, J. M. Yang, H. L. Lee, S. W. Lee, N. I. Han, S.‐H. Kim, M. J. Song, S. Hwang, P. S. Sung, J. W. Jang, S. H. Bae, J. Y. Choi, S. K
    Journal of Viral Hepatitis.2018; 25(10): 1189.     CrossRef
  • Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety
    Hye Won Lee, Se Rim Oh, Dong Yun Kim, Yechan Jeong, Seungtaek Kim, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park
    Gut and Liver.2018; 12(3): 324.     CrossRef
  • Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir: combined effects with mycophenolic acid
    Petra E de Ruiter, Yashna Gadjradj, Robert J de Knegt, Herold J Metselaar, Jan NM Ijzermans, Luc JW van der Laan
    World Journal of Transplantation.2018; 8(5): 156.     CrossRef
  • Asunaprevir/daclatasvir

    Reactions Weekly.2017; 1653(1): 56.     CrossRef
  • Global elimination of hepatitis C virus infection: Progresses and the remaining challenges
    Reza Taherkhani, Fatemeh Farshadpour
    World Journal of Hepatology.2017; 9(33): 1239.     CrossRef
  • 10,974 View
  • 215 Download
  • 12 Web of Science
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Clinical features and outcomes of gastric variceal bleeding: retrospective Korean multicenter data
Moon Young Kim, Soon Ho Um, Soon Koo Baik, Yeon Seok Seo, Soo Young Park, Jung Il Lee, Jin Woo Lee, Gab Jin Cheon, Joo Hyun Sohn, Tae Yeob Kim, Young Suk Lim, Tae Hyo Kim, Tae Hee Lee, Sung Jae Park, Seung Ha Park, Jin Dong Kim, Sang Young Han, Chang Soo Choi, Eun Young Cho, Dong Joon Kim, Jae Seok Hwang, Byoung Kuk Jang, June Sung Lee, Sang Gyune Kim, Young Seok Kim, So Young Kwon, Won Hyeok Choe, Chang Hyeong Lee, Byung Seok Kim, Jae Young Jang, Soung Won Jeong, Byung Ho Kim, Jae Jun Shim, Yong Kyun Cho, Moon Soo Koh, Hyun Woong Lee
Korean J Hepatol 2013;19(1):36-44.
Published online March 25, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.1.36
Background/Aims

While gastric variceal bleeding (GVB) is not as prevalent as esophageal variceal bleeding, it is reportedly more serious, with high failure rates of the initial hemostasis (>30%), and has a worse prognosis than esophageal variceal bleeding. However, there is limited information regarding hemostasis and the prognosis for GVB. The aim of this study was to determine retrospectively the clinical outcomes of GVB in a multicenter study in Korea.

Methods

The data of 1,308 episodes of GVB (males:females=1062:246, age=55.0±11.0 years, mean±SD) were collected from 24 referral hospital centers in South Korea between March 2003 and December 2008. The rates of initial hemostasis failure, rebleeding, and mortality within 5 days and 6 weeks of the index bleed were evaluated.

Results

The initial hemostasis failed in 6.1% of the patients, and this was associated with the Child-Pugh score [odds ratio (OR)=1.619; P<0.001] and the treatment modality: endoscopic variceal ligation, endoscopic variceal obturation, and balloon-occluded retrograde transvenous obliteration vs. endoscopic sclerotherapy, transjugular intrahepatic portosystemic shunt, and balloon tamponade (OR=0.221, P<0.001). Rebleeding developed in 11.5% of the patients, and was significantly associated with Child-Pugh score (OR=1.159, P<0.001) and treatment modality (OR=0.619, P=0.026). The GVB-associated mortality was 10.3%; mortality in these cases was associated with Child-Pugh score (OR=1.795, P<0.001) and the treatment modality for the initial hemostasis (OR=0.467, P=0.001).

Conclusions

The clinical outcome for GVB was better for the present cohort than in previous reports. Initial hemostasis failure, rebleeding, and mortality due to GVB were universally associated with the severity of liver cirrhosis.

Citations

Citations to this article as recorded by  Crossref logo
  • Treatment of Gastric Varices
    Thomas J. Wang, Marvin Ryou
    Current Hepatology Reports.2024; 23(2): 287.     CrossRef
  • Endoscopic Treatment and Prevention of Acute Variceal Hemorrhage
    Youngdae Kim
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2024; 24(1): 5.     CrossRef
  • Plug-Assisted Retrograde Transvenous Obliteration: A Modified Balloon-Occluded Retrograde Transvenous Obliteration of Gastric Varices
    Dong Il Gwon, Hyun-Ki Yoon
    Digestive Disease Interventions.2024; 08(03): 183.     CrossRef
  • Coil- and Plug-Assisted Transvenous Retrograde Obliteration (CARTO/PARTO) in the Treatment of Gastric Varices: A European Single Centre Experience
    Giuseppe Pelle, Flavio Andresciani, Massimo Messina, Silvia Nardelli, Lorenzo Ridola, Ermanno Notarianni, Adelchi Saltarelli, Stefania Gioia, Alessandro Tanzilli, Cesare Ambrogi
    Gastrointestinal Disorders.2024; 6(3): 742.     CrossRef
  • Ендоскопічне лікування кровотеч із варикозно розширених вен шлунка
    S.M. Chooklin, S.S. Chuklin, Ya.R. Dutka
    EMERGENCY MEDICINE.2022; 18(5): 44.     CrossRef
  • Diagnosis and Management of Esophageal and Gastric Variceal Bleeding: Focused on 2019 KASL Clinical Practice Guidelines for Liver Cirrhosis
    Min Kyung Park, Yun Bin Lee
    The Korean Journal of Gastroenterology.2021; 78(3): 152.     CrossRef
  • Comparison of the Effects of TIPS versus BRTO on Bleeding Gastric Varices: A Meta-Analysis
    Zi Wen Wang, Jin Chao Liu, Fang Zhao, Wen Guang Zhang, Xu Hua Duan, Peng Fei Chen, Si Fu Yang, Hong Wei Li, Fu Wen Chen, Hong Sheng Shi, Jian Zhuang Ren
    Canadian Journal of Gastroenterology and Hepatology.2020; 2020: 1.     CrossRef
  • KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications

    Clinical and Molecular Hepatology.2020; 26(2): 83.     CrossRef
  • Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) Versus Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Treatment of Gastric Varices Because of Portal Hypertension
    Swathi Paleti, Venkat Nutalapati, Jihan Fathallah, Sravan Jeepalyam, Tarun Rustagi
    Journal of Clinical Gastroenterology.2020; 54(7): 655.     CrossRef
  • Endoscopic Therapy and Radiologic Intervention of Acute Gastroesophageal Variceal Bleeding
    Jeong Eun Song, Byung Seok Kim
    Clinical Endoscopy.2019; 52(5): 407.     CrossRef
  • Detection of fundic varices obturation by endoscopic ultrasound versus multidetector computed tomography
    Amr Elrabat, Salah El-Gamal, Mohammad M. Kashwaa, Mohamed M. El-Rakhawy
    The Egyptian Journal of Internal Medicine.2019; 31(4): 487.     CrossRef
  • Plug-Assisted Retrograde Transvenous Obliteration for the Treatment of Gastric Varices: The Role of Intra-Procedural Cone-Beam Computed Tomography
    Dong Il Gwon, Gi-Young Ko, Young Baek Kwon, Hyun-Ki Yoon, Kyu-Bo Sung
    Korean Journal of Radiology.2018; 19(2): 223.     CrossRef
  • Prevention and management of gastroesophageal varices
    Yeon Seok Seo
    Clinical and Molecular Hepatology.2018; 24(1): 20.     CrossRef
  • Innovative Technique for Endoscopic Placement of Sengstaken-Blakemore Tube
    Arleen M. Ortiz, Cesar J. Garcia, Mohamed O. Othman, Marc J. Zuckerman
    Southern Medical Journal.2018; 111(5): 307.     CrossRef
  • Balloon-Occluded Retrograde Transvenous Obliteration versus Transjugular Intrahepatic Portosystemic Shunt for the Management of Gastric Variceal Bleeding
    Geunwu Gimm, Young Chang, Hyo-Cheol Kim, Aesun Shin, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
    Gut and Liver.2018; 12(6): 704.     CrossRef
  • Management of different types of gastric varices with band ligation: a 3-year experience
    Waseem M. Seleem, Amr S. Hanafy
    European Journal of Gastroenterology & Hepatology.2017; 29(8): 968.     CrossRef
  • Balloon‐occluded retrograde transvenous obliteration versus transjugular intrahepatic portosystemic shunt for treatment of gastric varices due to portal hypertension: A meta‐analysis
    Yun‐Bing Wang, Jian‐Ying Zhang, Jian‐Ping Gong, Fan Zhang, Yong Zhao
    Journal of Gastroenterology and Hepatology.2016; 31(4): 727.     CrossRef
  • Usefulness of intra-procedural cone-beam computed tomography in modified balloon-occluded retrograde transvenous obliteration of gastric varices
    Edward Wolfgang Lee, Naomi So, Ryan Chapman, Justin P McWilliams, Christopher T Loh, Ronald W Busuttil, Stephen T Kee
    World Journal of Radiology.2016; 8(4): 390.     CrossRef
  • Cyanoacrylate Injection Versus Band Ligation in the Endoscopic Management of Acute Gastric Variceal Bleeding
    Weiguang Qiao, Yutang Ren, Yang Bai, Side Liu, Qiang Zhang, Fachao Zhi
    Medicine.2015; 94(41): e1725.     CrossRef
  • Novel Use of Glidescope Indirect Laryngoscopy for Insertion of a Minnesota Tube for Variceal Bleeding
    Adam B. Schlichting, Jayna M. Gardner-Gray, Gina Hurst
    The Journal of Emergency Medicine.2015; 49(1): 40.     CrossRef
  • Re-Bleeding in Patients With Cirrhosis: Evaluation of Esophageal and Gastric Variceal Bleeding and Their Relationship With a Model for the End-Stage Liver Disease (MELD) Score and Child-Pugh Score
    Mohsen Ebrahimi, Hamidreza Reihani, Mohammadreza Sheikhian, Ehsan Bolvardi, Masumeh Pashayi, Elham Pishbin
    Razavi International Journal of Medicine.2014;[Epub]     CrossRef
  • Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension
    Jae Hyun Kim, Jung Min Kim, Youn Zoo Cho, Ji Hoon Na, Hyun Sik Kim, Hyoun A Kim, Hye Won Kang, Soon Koo Baik, Sang Ok Kwon, Seung Hwan Cha, Young Ju Kim, Moon Young Kim
    Clinical and Molecular Hepatology.2014; 20(4): 376.     CrossRef
  • The secondary prophylactic efficacy of beta-blocker after endoscopic gastric variceal obturation for first acute episode of gastric variceal bleeding
    Moon Han Choi, Young Seok Kim, Sang Gyune Kim, Yun Nah Lee, Yu Ri Seo, Min Jin Kim, Sae Hwan Lee, Soung Won Jeong, Jae Young Jang, Hong Soo Kim, Boo Sung Kim
    Clinical and Molecular Hepatology.2013; 19(3): 280.     CrossRef
  • 13,118 View
  • 86 Download
  • Crossref